HCSA Community Services and Tan Tock Seng Hospital Sign MOU to Hepatitis C Elimination in Singapore
SINGAPORE, July 28, 2025 /PRNewswire/ -- In celebration of the World Hepatitis Day (28 July), HCSA Community Services and Tan Tock Seng Hospital (TTSH), an anchor hospital of NHG Health, today signed a Memorandum of Understanding (MoU) to reinforce their shared commitment to eliminating Hepatitis C (HCV) among former drug offenders in Singapore, the World Health Organization's global strategy of eliminating Hepatitis C.
Representatives from HCSA Community Services, Tan Tock Seng Hospital Gastroenterology Department, National Centre for Infectious Diseases, Communicable Diseases Agency, Home Team Medical Services Division (MHA), Tzu-Chi Foundation (Singapore), Gilead Sciences, Singapore Prison Service, Singapore Anti-Narcotics Association, Prison Fellowship Singapore, Halfway house partners
This marks a significant step towards the Educate, Test, Treat! (ETT) initiative, launched in 2022 with the funding support of Gilead Sciences. Witnessed by Mdm Rahayu Mahzam, Minister of State, Ministry of Health and Ministry of Digital Development and Information, the MoU strengthens closer collaboration between community and healthcare stakeholders to expand HCV screening, and make care and treatment more accessible to prevent serious liver diseases.
Through this latest phase of the ETT Initiative, a continued partnership with TTSH has been formalized through a Memorandum of Understanding (MoU). This collaboration will strengthen follow-up care by combining fast, saliva-based Hepatitis C antibody testing, which avoids the need for blood draws or finger pricks, with access to specialist medical support.
From August 2025 to the end of 2026, the initiative aims to screen up to 600 individuals. TTSH will provide a comprehensive suite of services, including educational outreach, conducting HCV screenings, confirming chronic HCV infection with HCV viral load testing in the clinic, assessing for early signs of liver fibrosis, prescribing antiviral therapy, and confirming cure after treatment completion. The hospital will also connect patients with HCSA for financial guidance and support services.
The first phase of ETT initiative in 2023 achieved its target recruitment of 210 participants. Phase 2, launched in 2024, continues to aim to make Hepatitis C screening more accessible to ensure individuals receive timely medical care at the hospital. This phase expands its outreach by working closely with more halfway houses, targeting up to 400 participants for screening. To date, Phase 2, which will complete in 2025, has reached 85% of its screening target – Among them, 93% of participants who were tested HCV Antibody positive, and 68.5% of those who were confirmed with active HCV infection have received early and appropriate medical treatment. This progress has been made possible through strong collaboration among halfway houses and program partners like Gilead Sciences and Tzu Chi Foundation, providing essential medical, financial, and social support.
"This partnership marks a significant step to support former drug offenders in reclaiming their health and dignity. By breaking down barriers to care, we are not only treating a disease, but we are also restoring hope," said Mrs Kim Lang Khalil, Chief Executive Officer, HCSA Community Services.
"Tan Tock Seng Hospital remains committed to delivering specialist care beyond hospital walls and into the community. Through close collaboration with participating halfway houses, we are making tangible progress toward turning the vision of Hepatitis C elimination among former drug offenders in Singapore into reality," said Dr Yew Kuo Chao, Senior Consultant from the Department of Gastroenterology and Hepatology, Tan Tock Seng Hospital, NHG Health.
"At Gilead, we remain deeply committed to working closely and collaboratively with local partners to reach vulnerable populations, reduce health disparities, and ensure that every individual—regardless of background—has access to the care they need. In support of the WHO's hepatitis elimination goal, Gilead is proud to collaborate with HCSA Community Services and other local partners. We are encouraged to see this network grow stronger year by year, reflecting the power of partnership in driving meaningful change," said Ms. Cathy Su, General Manager, Taiwan, Hong Kong & Singapore, Gilead Sciences.
About HCSA Community Services
HCSA Community Services is a charitable organisation with Institution of a Public Character (IPC) status and a member of the National Council of Social Service. The organisation was launched in 1996 as a halfway house for recovering drug addicts and ex-offenders under its HCSA Highpoint programme. Today, their work has expanded to include teenage girls who have suffered complex trauma from abuse, single-parent families with limited support and other at-risk groups in the community. HCSA operates with a team of dedicated staff, volunteer teams, corporate and community partners, as they continue to serve the vulnerable in society, to give them a future and a hope. HCSA's mission is to empower these vulnerable populations through their signature programmes. Find out more at .
About Tan Tock Seng Hospital
Tan Tock Seng Hospital (TTSH), an anchor hospital of NHG Health, is one of Singapore's largest and pioneering multidisciplinary hospitals. Affectionately known as the People's Hospital, TTSH has a dedicated healthcare team of over 11,000, operates more than 2,000 beds, and provides care across more than 60 clinical disciplines. It is home to NHG Health's National Centre for Infectious Diseases (NCID) a 330-bed purpose-built facility designed to strengthen Singapore's capabilities in infectious disease management and prevention.
TTSH anchors HealthCity Novena—Singapore's first integrated healthcare hub, spanning 17 hectares, and as part of NHG Health, TTSH is committed to empowering individuals in Central and North Singapore to lead healthier lives, transforming care through innovation, research and clinical excellence — adding years of healthy life to the community.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
Jeremiah Barnabas
Senior Manager, Strategic Communications
+65 6745 3532 ext 456
Agnes Lau
Director of Public Affairs, Asia
+852 9551 9987